Literature DB >> 17201703

Epilepsy and the impact of an epileptology clinic for patients with mental retardation and associated disabilities in an institutional setting.

Amir Arain1, Bashir Shihabuddin, Faiz Niaz, Pradeep Modur, Henry Taylor, Toufic Fakhoury, Bassel Abou-Khalil.   

Abstract

PURPOSE: Epilepsy is a common problem in institutionalized patients with multiple handicaps. Limited data exist on the characteristics of epilepsy in this patient population and the impact of systematic evaluation by an epilepsy service.
METHODS: We evaluated 138 patients with epilepsy, institutionalized at a facility that cares for 324 patients with multiple handicaps. Evaluation included EEG, MRI, and video-EEG monitoring. The medication regimen was changed according to seizure diagnosis and the status of seizure control. Follow-up was available for >or=6 months in 110 patients, 1 year for 89, and 1.5 years for 49 patients. We analyzed the seizure and epilepsy diagnosis in this population, as well as the seizure frequency after evaluation and treatment.
RESULTS: The 76 male and 62 female patients' ages ranged from 14 to 73 years. Seventy-three patients had fewer than one seizure per month, whereas 29 patients had at least one seizure per month. Of 131 patients taking antiepileptic drugs (AEDs), 62 were receiving monotherapy, and 69 were receiving two or more AEDs. At the last follow-up, overall 55% of patients had reduced seizure frequency, including 23% who became seizure free. Two of 36 patients had spontaneous seizure recurrence after being seizure free with no AEDs for 4 months in one patient and 3 years for the other. Attempts were made to discontinue phenobarbital, primidone, and clonazepam in 21 patients. However, these were discontinued in only five patients.
CONCLUSIONS: Epilepsy is heterogeneous in institutionalized patients with multiple handicaps. It is often responsive to medical therapy. Evaluation and treatment by epilepsy specialists had an overall favorable impact on seizure control.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201703     DOI: 10.1111/j.1528-1167.2006.00862.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

1.  What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture.

Authors:  Jerome Engel
Journal:  Neurology       Date:  2016-12-06       Impact factor: 9.910

2.  Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication response.

Authors:  Jerzy P Szaflarski; Christopher J Lindsell; Tarek Zakaria; Christi Banks; Michael D Privitera
Journal:  Epilepsy Behav       Date:  2010-03-12       Impact factor: 2.937

3.  Risk of hospitalization and death for COVID-19 in persons with epilepsy over a 20-month period: The EpiLink Bologna cohort, Italy.

Authors:  Lorenzo Muccioli; Corrado Zenesini; Lisa Taruffi; Laura Licchetta; Barbara Mostacci; Lidia Di Vito; Elena Pasini; Lilia Volpi; Patrizia Riguzzi; Lorenzo Ferri; Flavia Baccari; Francesco Nonino; Roberto Michelucci; Paolo Tinuper; Luca Vignatelli; Francesca Bisulli
Journal:  Epilepsia       Date:  2022-07-17       Impact factor: 6.740

4.  Pregabalin in the management of partial epilepsy.

Authors:  Amir M Arain
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

5.  Seizure control in patients with epilepsy: the physician vs. medication factors.

Authors:  Jerzy P Szaflarski; Angela Y Rackley; Christopher J Lindsell; Magdalena Szaflarski; Stephen L Yates
Journal:  BMC Health Serv Res       Date:  2008-12-18       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.